Tirzepatide
Dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The synergistic effect results in superior glycaemic regulation and more potent appetite suppression than GLP-1 agonists alone.
- Substantial weight loss (>20% in trials)
- Powerful regulation of glucose and insulin
- Improved cardiovascular markers
- Central appetite suppressionSubstantial weight loss (>20% in trials)
- Central appetite suppression
- Nausea, vomiting, constipation (risk of gastroparesis).
Tirzepatida is an innovative dual agonist of the GIP (Gastric Inhibitory Polypeptide) and GLP-1 receptors, and is the first molecule in its class to demonstrate superior efficacy to standard treatments for diabetes and obesity.
READ MORE
What it is (in plain language)
- Known commercially as Mounjaro or Zepbound. While Ozempic uses one 'channel' to reduce hunger, Tirzepatide uses two. The additional channel (GIP) helps burn fat more intelligently and substantially reduces the side effects of nausea that occur with other drugs, allowing for higher doses and better results.
Why do you appear online so much
- It is currently considered the 'queen' of the slimming substances available on the market. The data shows an average weight loss of 20-25%, something never seen before outside of surgery, completely transforming metabolic medicine.
How it is framed today (pragmatic view)
- 1) Evidence: Massive clinical trials (SURMOUNT) with groundbreaking results. 2) Objective: Remission of type 2 diabetes and treatment of obesity. 3) Risk: Gastrointestinal effects may occur, although GIP helps mitigate them compared to Semaglutide.
How to use this form
- See the titration guide to understand how to safely increase doses over the months.
- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Metabolic
- Route: Injectable
- Tags: Injectable|Fat Loss|Approved
- Half-life: ~5 Days
- Start: 24-48 hours
- Duration: 7 days
- Mechanism (high level)
Dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The synergistic effect results in superior glycaemic regulation and more potent appetite suppression than GLP-1 agonists alone.
- Evidence (what the literature covers)
RESEARCH RANGE (Clinical, Non-prescriptive):
Approved (Mounjaro/Zepbound). Stepped doses from 2.5mg to 15mg weekly.
Level of Evidence: A (SURMOUNT/SURPASS Trials).
- Safety and harm-reduction (non-prescriptive)
Risks: Nausea, vomiting, constipation (risk of gastroparesis).
Interactions: Insulin (risk of hypoglycaemia).
- References (anchors)
- Rosenstock, J. (2021) - Tirzepatide SURPASS-1 phase 3 trial - https://doi.org/10.1016/S0140-6736(21)01324-6 | PubMed:34175104
- Jastreboff, A. M. (2022) - Tirzepatide for obesity SURMOUNT-1 - https://doi.org/10.1056/NEJMoa2206038 | PubMed:35658024
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL